BioCryst制药宣布,其药物Orladeyo®(贝罗曲司他)在2025年初步实现净收入6.01亿美元,较上年同期增长37%,表现优于公司先前公布的业绩指引范围。
BioCryst制药宣布,其药物Orladeyo®(贝罗曲司他)在2025年初步实现净收入6.01亿美元,较上年同期增长37%,表现优于公司先前公布的业绩指引范围。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.